Lee:Literature Transporters

{|cellspacing="5" cellpadding="10" style="background:#3674C2; width: 1000px;"
 * -valign="top"
 * style="background:#ffffff"|

Feel free to add articles ...


 * Recent OATP papers: PubMed, Cite-U-Like

Transporters general review

 * 1) Stanley LA, Horsburgh BC, Ross J, Scheer N, Wolf CR. Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior. Drug Metab Rev. 2009;41(1):27-65. (PMID: 19514970)
 * 2) Oswald S, Grube M, Siegmund W, Kroemer HK. Transporter-mediated uptake into cellular compartments. Xenobiotica. 2007 Oct-Nov;37(10-11):1171-95.
 * 3) Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res. 2009 Sep;26(9):2039-54.
 * 4) Li P, Wang GJ, Robertson TA, Roberts MS. Liver transporters in hepatic drug disposition: an update. Curr Drug Metab. 2009 Jun;10(5):482-98.
 * 5) Oostendorp RL, Beijnen JH, Schellens JH. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treat Rev. 2009 Apr;35(2):137-47.
 * 6) Srimaroeng C, Perry JL, Pritchard JB. Physiology, structure, and regulation of the cloned organic anion transporters. Xenobiotica. 2008 Jul;38(7-8):889-935.
 * 7) Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications.Pharm Res. 2007 Oct;24(10):1803-23. (pmid=17404808)
 * 8) Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res. 2009 Dec;50(12):2340-57. (pmid=19498215)
 * 9) DuBuske LM. The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf. 2005;28(9):789-801. (pmid=16119972)

OATP family general review

 * 1) Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004 Feb;447(5):653-65. (pmid=14579113)
 * 2) Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics. 2007 Jul;8(7):787-802. (pmid=18240907)

OATP knockout models

 * 1) Van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, Kenworthy KE, Schinkel AH.Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs.J Clin Invest. 2010 Aug 2;120(8):2942-52. doi: 10.1172/JCI42168. Epub 2010 Jul 19.2942-2952(PMID=20644253)
 * 2) Van de Steeg E, van Esch A, Wagenaar E, van der Kruijssen CM, van Tellingen O, Kenworthy KE, Schinkel AH.High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel.Clin Cancer Res. 2010 Nov 19. [Epub ahead of print] (PMID: 21097690)

Analysis: Methods

 * 1) Koellensperger G, Hann S.Ultra-fast HPLC-ICP-MS analysis of oxaliplatin in patient urine. Anal Bioanal Chem. 2010 May;397(1):401-6. Epub 2010 Feb 19.401-406 (PMID: 20165835)

OATP1B3

 * 1) Ismair MG, Stieger B, Cattori V, Hagenbuch B, Fried M, Meier PJ, Kullak-Ublick GA: Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology 2001, 121:1185-1190.
 * 2) Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, et al.: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001, 120:1689-1699.
 * 3) Jung D, Podvinec M, Meyer UA, Mangelsdorf DJ, Fried M, Meier PJ, Kullak-Ublick GA: Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology 2002, 122:1954-1966.
 * 4) Cui Y, Walter B: Influence of albumin binding on the substrate transport mediated by human hepatocyte transporters OATP2 and OATP8. J Gastroenterol 2003, 38:60-68.
 * 5) Letschert K, Keppler D, Konig J: Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004, 14:441-452.
 * 6) Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A: Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005, 4:815-818.
 * 7) Al Sarakbi W, Mokbel R, Salhab M, Jiang WG, Reed MJ, Mokbel K: The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer. Anticancer Res 2006, 26:4985-4990.
 * 8) Yamaguchi H, Okada M, Akitaya S, Ohara H, Mikkaichi T, Ishikawa H, Sato M, Matsuura M, Saga T, Unno M, et al.: Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res 2006, 47:1196-1202.
 * 9) Lockhart AC, Harris E, LaFleur BJ, Merchant NB, Washington MK, Resnick MB, Yeatman TJ, Lee W: Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. Clin Exp Gastroenterol 2008, 1:1-7.
 * 10) Lee W, Belkhiri A, Lockhart AC, Merchant N, Glaeser H, Harris EI, Washington MK, Brunt EM, Zaika A, Kim RB, et al.: Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res 2008, 68:10315-10323.
 * 11) Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, Taura K, Yasuchika K, Nitta T, Ikai I, et al.: Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009, 44:793-798.
 * 12) Yamaguchi H, Kobayashi M, Okada M, Takeuchi T, Unno M, Abe T, Goto J, Hishinuma T, Mano N: Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett 2008, 260:163-169.
 * 13) Baldes C, Koenig P, Neumann D, Lenhof HP, Kohlbacher O, Lehr CM: Development of a fluorescence-based assay for screening of modulators of human Organic Anion Transporter 1B3 (OATP1B3). Eur J Pharm Biopharm 2005.
 * 14) Briz O, Serrano MA, MacIas RI, Gonzalez-Gallego J, Marin JJ: Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J 2003, 371:897-905.
 * 15) Muto M, Onogawa T, Suzuki T, Ishida T, Rikiyama T, Katayose Y, Ohuchi N, Sasano H, Abe T, Unno M: Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci 2007, 98:1570-1576.
 * 16) Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005, 33:434-439.
 * 17) Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, et al.: Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008, 14:3312-3318.
 * 18) Gui C, Hagenbuch B: Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transport. Biochemistry 2008, 47:9090-9097.
 * 19) Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y: Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 2008, 99:967-972.
 * 20) Maeda T, Irokawa M, Arakawa H, Kuraoka E, Nozawa T, Tateoka R, Itoh Y, Nakanishi T, Tamai I: Uptake transporter organic anion transporting polypeptide 1B3 contributes to the growth of estrogen-dependent breast cancer. J Steroid Biochem Mol Biol 2010.
 * 21) Ichihara S, Kikuchi R, Kusuhara H, Imai S, Maeda K, Sugiyama Y: DNA methylation profiles of organic anion transporting polypeptide 1B3 in cancer cell lines. Pharm Res 2010, 27:510-516.

P-glycoprotein (MDR1)

 * 1) Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) I. Preclinical aspects. Drug Discov Today. 2007 Oct;12(19-20):833-7. (pmid=17933684)
 * 2) Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. Drug Discov Today. 2007 Oct;12(19-20):838-43. (pmid=17933685)
 * 3) pmid=17766652

bile acid signaling

 * 1) Donnellan F, Keating N, Geoghegan P, Murray FE, Harvey BJ, Keely SJ. JNK mitogen-activated protein kinase limits calcium-dependent chloride secretion across colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2010 Jan;298(1):G37-44. Epub 2009 Oct 29. PMID: 19875701
 * 2) Zucchini-Pascal N, de Sousa G, Pizzol J, Rahmani R. Pregnane X receptor activation protects rat hepatocytes against deoxycholic acid-induced apoptosis. Liver Int. 2010 Feb;30(2):284-97. Epub 2009 Sep 8. PMID: 19737350
 * 3) Sommerfeld A, Reinehr R, Häussinger D. Bile acid-induced epidermal growth factor receptor activation in quiescent rat hepatic stellate cells can trigger both proliferation and apoptosis. J Biol Chem. 2009 Aug 14;284(33):22173-83. Epub 2009 Jun 24. PMID: 19553664
 * 4) Takeuchi K, Shin-ya T, Nishio K, Ito F. Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase. FEBS J. 2009 Mar;276(5):1255-65. PMID: 19175673
 * 5) Ding G, Zhang A, Huang S, Pan X, Zhen G, Chen R, Yang T. ANG II induces c-Jun NH2-terminal kinase activation and proliferation of human mesangial cells via redox-sensitive transactivation of the EGFR. Am J Physiol Renal Physiol. 2007 Dec;293(6):F1889-97. Epub 2007 Sep 19. PMID: 17881465
 * 6) Cáceres M, Tobar N, Guerrero J, Smith PC, Martínez J. c-jun-NH2JNK mediates invasive potential and EGFR activation by regulating the expression of HB-EGF in a urokinase-stimulated pathway. J Cell Biochem. 2008 Feb 15;103(3):986-93. PMID: 17654528
 * 7) Reinehr R, Becker S, Wettstein M, Häussinger D. Involvement of the Src family kinase yes in bile salt-induced apoptosis. Gastroenterology. 2004 Nov;127(5):1540-57.PMID: 15521021
 * 8) Qiao L, Han SI, Fang Y, Park JS, Gupta S, Gilfor D, Amorino G, Valerie K, Sealy L, Engelhardt JF, Grant S, Hylemon PB, Dent P. Bile acid regulation of C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes. Mol Cell Biol. 2003 May;23(9):3052-66. PMID: 12697808
 * 9) Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology. 2002 Apr;122(4):985-93. PMID: 11910351
 * 10) Qiao L, Studer E, Leach K, McKinstry R, Gupta S, Decker R, Kukreja R, Valerie K, Nagarkatti P, El Deiry W, Molkentin J, Schmidt-Ullrich R, Fisher PB, Grant S, Hylemon PB, Dent P. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Mol Biol Cell. 2001 Sep;12(9):2629-45. PMID: 11553704
 * 11) Chen K, Vita JA, Berk BC, Keaney JF Jr. c-Jun N-terminal kinase activation by hydrogen peroxide in endothelial cells involves SRC-dependent epidermal growth factor receptor transactivation. J Biol Chem. 2001 May 11;276(19):16045-50. Epub 2001 Feb 27. PMID: 11278982